. Author manuscript; available in PMC: 2009 Sep 14.

Published in final edited form as: Biol Blood Marrow Transplant. 2007 Mar 21;13(6):655–664. doi: 10.1016/j.bbmt.2007.01.079

Table 4.

Summary of new grouping scheme

Group	AML	MDS or AML arising from MDS
Favorable	t(8;21) alone inv(16)/t(16;16)/del(16q22) with M4 t(15;17)
Standard-risk	Normal del(9q) t(8;21) + del(9q) or complex Trisomy 8 Abnormal 5 or 7 Abnormal 11q23 All others	Normal Abnormal 3q Abnormal 5 Trisomy 8 All others
Adverse	Complex t(9;22) t(6;9)	Abnormal 7 Complex

Patients with AML and abnormal 3q, as well as patients with MDS and 5q-, 20q-, or Y- are not classified in this analysis, as too few patients with those abnormalities were present in our cohort to assign to a risk group